Today, investors in Bionano Genomics and BNGO stock are cheering some positive clinical trial data around optical genome mapping. The post BNGO Stock: What Is Driving Bionano Genomics Higher Today?
SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced the publication of the largest clinical research study to date evaluating optical genome mapping (OGM) for f

3 Top Tech Stocks to Buy on Weakness

10:35am, Tuesday, 21'st Sep 2021
All three of these tech names, driven by very strong positive catalysts, should rally over the longer term, leading to high profits for investors. The post 3 Top Tech Stocks to Buy on Weakness appeare
BNGO stock has been stuck in a range, but its next move should be to the upside based on Bionano's breakthrough genome mapping system. The post Bionano Genomics Remains Promising With Global Product A
These under-the-radar companies are expected to deliver jaw-dropping revenue growth over the next four years.
SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, C
With its Saphyr system seeing adoption ramp up, the long-term growth potential for BNGO stock is considerable. The post The Price Is Right for BioNano Genomics Given Saphyr's Potential appeared first
As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock. The post Bionano Stock Will Soar as the Company's Diagnostic System C
Bionano Genomics is mastering the science of genome mapping, while a reduced-price BNGO stock has a clear path forward for investors. The post Faster and Better Clinical Outcomes Make the Case for Bio
Bionano Genomics' (BNGO) CEO Erik Holmlin on Q2 2021 Results - Earnings Call Transcript
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -20.00% and 16.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the second quarter ended June 30, 2021 and highlighted
Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals.
Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 4, 2021 at 4:30 p.m. Easter
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE